Biotech Values

[north40000]

True...and meantime the indicated uses for Vascepa continue to accumulate beyond this droplink collection, now needing updating:

https://dl.dropboxusercontent.com/u/57678878/Compilation%20of%20EPA%20Scientific%20Articles%20.pdf

A search of poster "zumantu" on AMRN IHub board will reveal extensive posts of scientific literature re EPA effects in humans.

Recall Amarin won 2 suits against the FDA in 2015. Today's NCE is the result of the 1st win . No doubt FDA Law Blog authors will report in the next few days. The 2nd win against FDA in October 2015, involving Constitutional issues of 1st Amendment right of Amarin to promote and market Vascepa to doctors and hospitals for off-label uses with truthful and non-misleading statements, has been settled.

Price targets for Amarin are all over the map. I have been covered by insurance for an off-label prescription of Vascepa since April 2013.